Ilatreotide

Ilatreotide (SDZ CO61), glycated somatostatin derivative, is a highly potent glycated analog of somatostatin with improved oral activity. Ilatreotide can suppress the fasting level and postprandial release of several gastrointestinal and pancreatic hormones. Ilatreotide can be used for the research of gastroenteropancreatic tumors[1][2][3].

C[C@@H](O)[C@H]1C(N[C@H](C(N[C@@H]([C@H](O)C)CO)=O)CSSC[C@H](NC([C@H](NC[C@]2(O)[C@@H](O)[C@H](O[C@@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H](O)CO2)CC4=CC=CC=C4)=O)C(N[C@@H](CC5=CC=CC=C5)C(N[C@H](CC6=CNC7=CC=CC=C76)C(N[C@@H](CCCCN)C(N1)=O)=O)=O)=O)=O

[1]Drum, et al. Use of somatostatin analogs in myocardial perfusion imaging. Patent. WO2008143958 A1.|[2]Nelson-Piercy C, et al. Effect of a new oral somatostatin analog (SDZ CO 611) on gastric emptying, mouth to cecum transit time, and pancreatic and gut hormone release in normal male subjects. J Clin Endocrinol Metab. 1994 Feb;78(2):329-36.|[3]Albert R,et al. SDZ CO 611: a highly potent glycated analog of somatostatin with improved oral activity. Life Sci. 1993;53(6):517-25.